戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 igase) is a key target for the design of new antitubercular agents.
2 tency greater than that of many conventional antitubercular agents.
3 ntify small molecule inhibitors as potential antitubercular agents.
4            This makes the discovery of novel antitubercular agents a cogent priority.
5 ine action where chlorpromazine, a promising antitubercular agent and key medicine used to treat psyc
6 is (Mtb) to look for inducible expression of antitubercular agents and identified 5 fungi that produc
7  that can be exploited for the design of new antitubercular agents and/or diagnostic tools.
8 -carboxamide analogue, 3, as a highly potent antitubercular agent, and the subsequent chemical modifi
9 alues lower than those of the most prominent antitubercular agents currently in use.
10 re a promising class of potent and selective antitubercular agents, if the metabolic liability can be
11                                          The antitubercular agent isoniazid can be activated by Mycob
12                                              Antitubercular agent levesquamide is a new polyketide-no
13 y, alone and in combination with second-line antitubercular agents (moxifloxacin or bedaquiline), the
14 icals found with KatG, while the less potent antitubercular agent nicotinic acid hydrazide produced t
15 rotein and a validated target to develop new antitubercular agents, particularly for the treatment of
16 rotein and a validated target to develop new antitubercular agents, particularly for the treatment of
17     The urgent need for safer and innovative antitubercular agents remains a priority for the scienti
18        Application of MycoBCP to a series of antitubercular agents successfully identified known MOAs
19 derscores the urgent need for new classes of antitubercular agents targeting novel pathways.
20             Pretomanid and delamanid are new antitubercular agents that have progressed through the d
21  (Sal-AMS) is a prototype for a new class of antitubercular agents that inhibit the aryl acid adenyla
22 red the discovery of a novel class of potent antitubercular agents that unexpectedly possessed notabl
23 s and identified 5 fungi that produced cidal antitubercular agents upon exposure to live Mtb.
24  The potential of compound 5f as a promising antitubercular agent was further strengthened by in sili
25       In this work, rifampicin, a first-line antitubercular agent, was encapsulated into biocompatibl
26 elevant for increasing the concentrations of antitubercular agents within the infected site and reduc